These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24123383)

  • 1. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
    Lang AE; Eberly S; Goetz CG; Stebbins G; Oakes D; Marek K; Ravina B; Tanner CM; Shoulson I;
    Mov Disord; 2013 Dec; 28(14):1980-6. PubMed ID: 24123383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease.
    Gallagher DA; Goetz CG; Stebbins G; Lees AJ; Schrag A
    Mov Disord; 2012 Jan; 27(1):79-83. PubMed ID: 21915909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale.
    Martinez-Martin P; Chaudhuri KR; Rojo-Abuin JM; Rodriguez-Blazquez C; Alvarez-Sanchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martinez-Castrillo JC; Mendoza-Rodriguez A; Moore HP; Rodriguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
    Eur J Neurol; 2015 Jan; 22(1):37-43. PubMed ID: 23607783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease.
    Rodriguez-Blazquez C; Rojo-Abuin JM; Alvarez-Sanchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martinez-Castrillo JC; Mendoza-Rodriguez A; Moore HP; Rodriguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG; Martinez-Martin P
    Parkinsonism Relat Disord; 2013 Oct; 19(10):889-93. PubMed ID: 23791519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scales for assessing nonmotor symptom severity changes in Parkinson's disease patients with symptom fluctuations.
    Buck PO; Trautman H; Clark J
    Int J Neurosci; 2010 Aug; 120(8):523-30. PubMed ID: 20615055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
    Skorvanek M; Rosenberger J; Minar M; Grofik M; Han V; Groothoff JW; Valkovic P; Gdovinova Z; van Dijk JP
    J Neurol Sci; 2015; 353(1-2):87-91. PubMed ID: 25918077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
    Goetz CG; Tilley BC; Shaftman SR; Stebbins GT; Fahn S; Martinez-Martin P; Poewe W; Sampaio C; Stern MB; Dodel R; Dubois B; Holloway R; Jankovic J; Kulisevsky J; Lang AE; Lees A; Leurgans S; LeWitt PA; Nyenhuis D; Olanow CW; Rascol O; Schrag A; Teresi JA; van Hilten JJ; LaPelle N;
    Mov Disord; 2008 Nov; 23(15):2129-70. PubMed ID: 19025984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actigraphy monitoring of symptoms in patients with Parkinson's disease.
    Pan W; Kwak S; Li F; Wu C; Chen Y; Yamamoto Y; Cai D
    Physiol Behav; 2013 Jul; 119():156-60. PubMed ID: 23748129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
    Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
    Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.
    Martínez-Martín P; Rodríguez-Blázquez C; Forjaz MJ; Alvarez-Sánchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martínez-Castrillo JC; Mendoza-Rodríguez A; Moore HP; Rodríguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
    Eur J Neurol; 2014 Mar; 21(3):519-24. PubMed ID: 24447695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
    Siderowf A; McDermott M; Kieburtz K; Blindauer K; Plumb S; Shoulson I;
    Mov Disord; 2002 Jul; 17(4):758-63. PubMed ID: 12210871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationships between the unified Parkinson's disease rating scale and lower extremity functional performance in persons with early-stage Parkinson's disease.
    Song J; Fisher BE; Petzinger G; Wu A; Gordon J; Salem GJ
    Neurorehabil Neural Repair; 2009 Sep; 23(7):657-61. PubMed ID: 19336530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS).
    Goetz CG; Stebbins GT; Chmura TA; Fahn S; Poewe W; Tanner CM
    Mov Disord; 2010 Jul; 25(9):1190-4. PubMed ID: 20629138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson's disease.
    Verbaan D; van Rooden SM; Benit CP; van Zwet EW; Marinus J; van Hilten JJ
    Parkinsonism Relat Disord; 2011 Sep; 17(8):632-4. PubMed ID: 21696993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
    Poewe W; Hauser RA; Lang A;
    Mov Disord; 2015 Apr; 30(4):589-92. PubMed ID: 25545629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal metric properties of disability rating scales for Parkinson's disease.
    Martinez-Martin P; Prieto L; Forjaz MJ
    Value Health; 2006; 9(6):386-93. PubMed ID: 17076869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative responsiveness of Parkinson's disease scales to change over time.
    Schrag A; Spottke A; Quinn NP; Dodel R
    Mov Disord; 2009 Apr; 24(6):813-8. PubMed ID: 19199355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.